Yaron Werber analyst TD COWEN

Currently out of the existing stock ratings of Yaron Werber, 137 are a BUY (72.87%), 50 are a HOLD (26.6%), 1 are a SELL (0.53%).

Yaron Werber

Work Performance Price Targets & Ratings Chart

Analyst Yaron Werber, currently employed at TD COWEN, carries an average stock price target met ratio of 63.32% that have a potential upside of 23.17% achieved within 351 days.

Yaron Werber’s has documented 373 price targets and ratings displayed on 40 stocks. The coverage is on Healthcare, Consumer Defensive sectors.

Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 09-Sep-2026.

Wall Street Analyst Yaron Werber

Analyst best performing recommendations are on GMAB (GENMAB AS).
The best stock recommendation documented was for ARGX (ARGENX NV ADR) at 7/17/2023. The price target of $533 was fulfilled within 3 days with a profit of $48.57 (10.03%) receiving and performance score of 33.42.

Average potential price target upside

AMGN Amgen ARGX argenx NV ADR BGNE BeiGene Ltd FGEN FibroGen RARE Ultragenyx XLRN Acceleron Pharma BLUE Bluebird bio EPZM Epizyme REGN Regeneron Pharmaceuticals ASND Ascendis Pharma AS ROIV Roivant Sciences Ltd TIL Instil Bio TSVT 2Seventy Bio EXEL Exelixis BNTX BioNTech SE GILD Gilead Sciences IOBT IO Biotech GBIO Generation Bio Co ORTX Orchard Therapeutics PLC GMAB Genmab AS IONS Ionis Pharmaceuticals LEGN Legend Biotech Corp STOK Stoke Therapeutics CELG Celgene COGT Cogent Biosciences PRVL Prevail Therapeutics SWTX SpringWorks Therapeutics ALEC Alector CLDX Celldex Therapeutics IMRX Immuneering Corp JSPR Jasper Therapeutics RAPT RAPT Therapeutics RLAY Relay Therapeutics AGIO Agios Pharm BG Bunge BIIB Biogen CLVS Clovis Oncology FG F&G Annuities & Life ICPT Intercept Pharmaceuticals PBYI Puma Biotechnology

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Sep-2023

$425

$10.39 (2.51%)

$320

20 days ago
(10-Sep-2026)

1/2 (50%)

$42.53 (11.12%)

797

Hold Since 07-Oct-2024

$400

$-14.61 (-3.52%)

$400

22 days ago
(08-Sep-2026)

32/35 (91.43%)

$6.83 (1.74%)

269

Buy Since 12-Apr-2024

$450

$35.39 (8.54%)

$450

22 days ago
(08-Sep-2026)

32/34 (94.12%)

$56.83 (14.45%)

567

Hold Since 10-Jan-2025

$435

$20.39 (4.92%)

$400

26 days ago
(04-Sep-2026)

20/21 (95.24%)

$-2.23 (-0.51%)

307

Buy Since 02-Jan-2025

$457

$42.39 (10.22%)

$427

1 months 10 days ago
(20-Aug-2026)

14/15 (93.33%)

$25.79 (5.98%)

160

Show more analysts

Please expand the browser size to see the chart

Which stock is Yaron Werber most bullish on?

Potential upside of $115.4 has been obtained for ASND (ASCENDIS PHARMA AS)

Which stock is Yaron Werber most reserved on?

Potential downside of -$3.16 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Yaron Werber?

On 2008
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?